| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702714 | Urologic Oncology: Seminars and Original Investigations | 2017 | 7 Pages |
Abstract
Caveolin-1 is overexpressed in one-third of patients with BCa treated with RC. Overexpression of Caveolin-1 is significantly associated with OS and CSS, but not with RFS, in patients with BCa treated with RC. However, it is not clinically useful as it does not improve upon the predictive accuracy of survival achieved by pathologic variables alone.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Francesco M.D., Ilaria M.D., Marco M.D., Romain M.D., Morgan M.D., Pierre I. M.D., Alberto M.D., Michael M.D., Kilian M. M.D., Melanie R. M.D., Beat M.D., Mohammad M.D., Andrea M.D., Tobias M.D., Shahrokh F. M.D.,